Madhusudhan Tarigopula1, Robert T Davis1, Paul T Mungai1, David M Ryba1, David F Wieczorek2, Conrad L Cowan3, Jonathan D Violin3, Beata M Wolska4, R John Solaro5. 1. Department of Physiology and Biophysics and Center for Cardiovascular Research, College of Medicine, University of Illinois, 835 S. Wolcott Avenue, Chicago, IL 60612-7342, USA. 2. Department of Molecular Genetics, Biochemistry and Microbiology, University of Cincinnati Medical Center, Cincinnati, OH, USA. 3. Trevena Inc., King of Prussia, PA, USA. 4. Department of Physiology and Biophysics and Center for Cardiovascular Research, College of Medicine, University of Illinois, 835 S. Wolcott Avenue, Chicago, IL 60612-7342, USA Department of Medicine, Division of Cardiology, University of Illinois, Chicago, IL, USA. 5. Department of Physiology and Biophysics and Center for Cardiovascular Research, College of Medicine, University of Illinois, 835 S. Wolcott Avenue, Chicago, IL 60612-7342, USA solarorj@uic.edu.
Abstract
AIMS: Therapeutic approaches to treat familial dilated cardiomyopathy (DCM), which is characterized by depressed sarcomeric tension and susceptibility to Ca(2+)-related arrhythmias, have been generally unsuccessful. Our objective in the present work was to determine the effect of the angiotensin II type 1 receptor (AT1R) biased ligand, TRV120023, on contractility of hearts of a transgenic mouse model of familial DCM with mutation in tropomyosin at position 54 (TG-E54K). Our rationale is based on previous studies, which have supported the hypothesis that biased G-protein-coupled receptor ligands, signalling via β-arrestin, increase cardiac contractility with no effect on Ca(2+) transients. Our previous work demonstrated that the biased ligand TRV120023 is able to block angiotensin-induced hypertrophy, while promoting an increase in sarcomere Ca(2+) response. METHODS AND RESULTS: We tested the hypothesis that the depression in cardiac function associated with DCM can be offset by infusion of the AT1R biased ligand, TRV120023. We intravenously infused saline, TRV120023, or the unbiased ligand, losartan, for 15 min in TG-E54K and non-transgenic mice to obtain left ventricular pressure-volume relations. Hearts were analysed for sarcomeric protein phosphorylation. Results showed that the AT1R biased ligand increases cardiac performance in TG-E54K mice in association with increased myosin light chain-2 phosphorylation. CONCLUSION: Treatment of mice with an AT1R biased ligand, acting via β-arrestin signalling, is able to induce an increase in cardiac contractility associated with an increase in ventricular myosin light chain-2 phosphorylation. AT1R biased ligands may prove to be a novel inotropic approach in familial DCM. Published on behalf of the European Society of Cardiology. All rights reserved.
AIMS: Therapeutic approaches to treat familial dilated cardiomyopathy (DCM), which is characterized by depressed sarcomeric tension and susceptibility to Ca(2+)-related arrhythmias, have been generally unsuccessful. Our objective in the present work was to determine the effect of the angiotensin II type 1 receptor (AT1R) biased ligand, TRV120023, on contractility of hearts of a transgenic mouse model of familial DCM with mutation in tropomyosin at position 54 (TG-E54K). Our rationale is based on previous studies, which have supported the hypothesis that biased G-protein-coupled receptor ligands, signalling via β-arrestin, increase cardiac contractility with no effect on Ca(2+) transients. Our previous work demonstrated that the biased ligand TRV120023 is able to block angiotensin-induced hypertrophy, while promoting an increase in sarcomere Ca(2+) response. METHODS AND RESULTS: We tested the hypothesis that the depression in cardiac function associated with DCM can be offset by infusion of the AT1R biased ligand, TRV120023. We intravenously infused saline, TRV120023, or the unbiased ligand, losartan, for 15 min in TG-E54K and non-transgenic mice to obtain left ventricular pressure-volume relations. Hearts were analysed for sarcomeric protein phosphorylation. Results showed that the AT1R biased ligand increases cardiac performance in TG-E54Kmice in association with increased myosin light chain-2 phosphorylation. CONCLUSION: Treatment of mice with an AT1R biased ligand, acting via β-arrestin signalling, is able to induce an increase in cardiac contractility associated with an increase in ventricular myosin light chain-2 phosphorylation. AT1R biased ligands may prove to be a novel inotropic approach in familial DCM. Published on behalf of the European Society of Cardiology. All rights reserved.
Authors: Sarah B Scruggs; Lori A Walker; Theodore Lyu; David L Geenen; R John Solaro; Peter M Buttrick; Paul H Goldspink Journal: J Mol Cell Cardiol Date: 2006-01-30 Impact factor: 5.000
Authors: Joanne Layland; Alison C Cave; Chad Warren; David J Grieve; Emma Sparks; Jonathan C Kentish; R John Solaro; Ajay M Shah Journal: FASEB J Date: 2005-04-26 Impact factor: 5.191
Authors: K Kimura; M Ito; M Amano; K Chihara; Y Fukata; M Nakafuku; B Yamamori; J Feng; T Nakano; K Okawa; A Iwamatsu; K Kaibuchi Journal: Science Date: 1996-07-12 Impact factor: 47.728
Authors: M Charlotte Olsson; Jitandrakumar R Patel; Daniel P Fitzsimons; Jeffery W Walker; Richard L Moss Journal: Am J Physiol Heart Circ Physiol Date: 2004-08-26 Impact factor: 4.733
Authors: David M Ryba; Jieli Li; Conrad L Cowan; Brenda Russell; Beata M Wolska; R John Solaro Journal: Circulation Date: 2017-01-19 Impact factor: 29.690
Authors: Steven J Forrester; George W Booz; Curt D Sigmund; Thomas M Coffman; Tatsuo Kawai; Victor Rizzo; Rosario Scalia; Satoru Eguchi Journal: Physiol Rev Date: 2018-07-01 Impact factor: 37.312
Authors: Ama Dedo Okyere; Jianliang Song; Viren Patwa; Rhonda L Carter; Nitya Enjamuri; Anna Maria Lucchese; Jessica Ibetti; Claudio de Lucia; Sarah M Schumacher; Walter J Koch; Joseph Y Cheung; Jeffrey L Benovic; Douglas G Tilley Journal: Cardiovasc Drugs Ther Date: 2022-01-08 Impact factor: 3.947